Cost‐effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration

The objective of this paper is to assess whether cardiac contractility modulation (via the Optimizer System) plus standard of care (SoC) is a cost‐effective treatment for people with heart failure [New York Heart Association (NYHA) III, left ventricular ejection fraction of 25–45%, and narrow QRS] compared against SoC alone from the perspective of the English National Health Service.

[1]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[2]  D. Burkhoff,et al.  A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. , 2011, American heart journal.

[3]  D. Burkhoff,et al.  Nonexcitatory, cardiac contractility modulation electrical impulses: Feasibility study for advanced heart failure in patients with normal QRS duration , 2006 .

[4]  L. Lund,et al.  Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. , 2013, European heart journal.

[5]  N. Maniadakis,et al.  Economic Evaluation of Cardiac Contractility Modulation (CCM) Therapy with the Optimizer IVs in the Management of Heart Failure Patients , 2015 .

[6]  D. Burkhoff,et al.  Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. , 2011, Journal of cardiac failure.

[7]  G. Hindricks,et al.  Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. , 2008, European heart journal.

[8]  D. Burkhoff,et al.  Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. , 2009, JACC. Cardiovascular imaging.

[9]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[10]  G. Hindricks,et al.  Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. , 2005, Journal of the American College of Cardiology.

[11]  M. Sculpher,et al.  Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure , 2016, Heart.

[12]  M. Cowie,et al.  Cost‐Effectiveness of Ivabradine for Heart Failure in the United States , 2016, Journal of the American Heart Association.

[13]  D. Burkhoff,et al.  Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients. , 2015, International journal of cardiology.

[14]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[15]  Tim Smith,et al.  Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  G. Boriani,et al.  Cardiac Resynchronization Therapy: An Overview on Guidelines. , 2017, Heart failure clinics.

[18]  J. Daubert,et al.  Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2006, European heart journal.

[19]  Liang Tang,et al.  Effectiveness of Implantation of Cardioverter-Defibrillators Therapy in Patients with Non-Ischemic Heart Failure: an Updated Systematic Review and Meta-Analysis , 2017, Brazilian journal of cardiovascular surgery.

[20]  D. Burkhoff,et al.  Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). , 2019, International journal of cardiology.

[21]  M. Sculpher,et al.  The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective , 2014, Heart.

[22]  D. Burkhoff,et al.  A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. , 2018, JACC. Heart failure.

[23]  Wolfgang Schramm,et al.  Team , 2018, Spaces of Intensity.

[24]  A. Goette,et al.  Cardiac contractility modulation improves long‐term survival and hospitalizations in heart failure with reduced ejection fraction , 2019, European journal of heart failure.

[25]  N. Bayley,et al.  Failure , 1890, The Hospital.

[26]  M. Dayer,et al.  31 The New National Institute for Health and Care Excellence (NICE) TA314 Guidelines may have a Significant Impact on Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronisation Therapy (CRT) Implant Rates in District General Hospitals , 2015, Heart.